Cencora, Inc. (NYSE:COR) Shares Acquired by Quantinno Capital Management LP

Quantinno Capital Management LP lifted its position in shares of Cencora, Inc. (NYSE:COR - Free Report) by 78.6% during the 3rd quarter, according to its most recent disclosure with the SEC. The firm owned 24,838 shares of the company's stock after buying an additional 10,933 shares during the period. Quantinno Capital Management LP's holdings in Cencora were worth $5,591,000 as of its most recent SEC filing.

A number of other hedge funds have also recently bought and sold shares of COR. Pacer Advisors Inc. raised its holdings in Cencora by 6,855.3% in the third quarter. Pacer Advisors Inc. now owns 2,065,374 shares of the company's stock valued at $464,874,000 after buying an additional 2,035,679 shares during the period. Bank of Montreal Can raised its stake in shares of Cencora by 136.8% in the 2nd quarter. Bank of Montreal Can now owns 641,887 shares of the company's stock valued at $153,623,000 after acquiring an additional 370,841 shares during the period. American Century Companies Inc. raised its stake in shares of Cencora by 155.0% in the 2nd quarter. American Century Companies Inc. now owns 598,438 shares of the company's stock valued at $134,828,000 after acquiring an additional 363,796 shares during the period. Eagle Asset Management Inc. lifted its holdings in shares of Cencora by 32.9% during the 3rd quarter. Eagle Asset Management Inc. now owns 1,009,454 shares of the company's stock valued at $250,758,000 after acquiring an additional 249,739 shares in the last quarter. Finally, Caisse DE Depot ET Placement DU Quebec increased its holdings in Cencora by 119.6% in the 3rd quarter. Caisse DE Depot ET Placement DU Quebec now owns 420,305 shares of the company's stock valued at $94,602,000 after purchasing an additional 228,881 shares in the last quarter. Institutional investors and hedge funds own 97.52% of the company's stock.

Cencora Stock Down 0.4 %

Shares of NYSE:COR traded down $0.90 during midday trading on Friday, reaching $243.41. The company had a trading volume of 1,199,812 shares, compared to its average volume of 1,126,541. The stock has a market capitalization of $47.05 billion, a P/E ratio of 32.41, a PEG ratio of 1.65 and a beta of 0.45. The stock's fifty day moving average price is $237.12 and its 200-day moving average price is $233.46. The company has a debt-to-equity ratio of 4.84, a current ratio of 0.88 and a quick ratio of 0.53. Cencora, Inc. has a one year low of $195.83 and a one year high of $253.27.

Cencora Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, November 29th. Stockholders of record on Friday, November 15th were given a $0.55 dividend. The ex-dividend date of this dividend was Friday, November 15th. This represents a $2.20 annualized dividend and a dividend yield of 0.90%. This is an increase from Cencora's previous quarterly dividend of $0.51. Cencora's payout ratio is presently 29.29%.

Insider Transactions at Cencora

In related news, Chairman Steven H. Collis sold 50,000 shares of the firm's stock in a transaction on Monday, November 25th. The stock was sold at an average price of $243.97, for a total transaction of $12,198,500.00. Following the transaction, the chairman now directly owns 326,557 shares in the company, valued at $79,670,111.29. This trade represents a 13.28 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. In the last 90 days, insiders sold 93,018 shares of company stock valued at $22,478,942. Insiders own 15.80% of the company's stock.

Analyst Ratings Changes

A number of research analysts have commented on COR shares. StockNews.com cut Cencora from a "strong-buy" rating to a "buy" rating in a research note on Friday, September 20th. UBS Group boosted their price target on Cencora from $275.00 to $285.00 and gave the stock a "buy" rating in a research report on Thursday, November 7th. Robert W. Baird upped their price target on Cencora from $287.00 to $292.00 and gave the stock an "outperform" rating in a report on Thursday, November 7th. Evercore ISI lifted their price objective on shares of Cencora from $250.00 to $285.00 and gave the company an "outperform" rating in a research note on Thursday, November 7th. Finally, Leerink Partners decreased their target price on shares of Cencora from $277.00 to $275.00 and set an "outperform" rating for the company in a research note on Monday, October 7th. Two equities research analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $276.80.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.